Ginkgo Bioworks Holdings Inc.
DNA evidence brief
What we can confirm
- BioSniper Score:
- 4.4 / 10
- Market Cap:
- $456.6M
What it means
What to watch
Prepared research question
What matters most for DNA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · DNA
Ginkgo Bioworks Holdings Inc. (DNA) is a synthetic biology company focused on cell programming and biosecurity, with a current cash position of $84.5M as of 2026-06-30 and ongoing partnerships in RNA medicine and AI drug discovery.
Key risk: Cash burn rate
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$456.6M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Ginkgo Bioworks Holdings Inc. (DNA) is a synthetic biology company focused on cell programming and biosecurity, with a current cash position of $84.5M as of 2026-06-30 and ongoing partnerships in RNA medicine and AI drug discovery.
- Cash & equivalents of $84.5M as of 2026-06-30 [sec]
- Total revenue of $20.2M and net income of -$46.7M as of 2026-06-30 [sec]
- Shareholders' equity of $420.3M as of 2026-06-30 [sec]
- Awarded a subcontract for up to $17.5M under the ARPA-H GIVE program for RNA medicine manufacturing [news · 2026-09-10]
- Entered a strategic partnership with Inductive Bio to scale AI drug discovery via Datapoints platform [news · 2025-08-20]
What works
- Multiple government-funded partnerships (ARPA-H GIVE, CATALYST) provide non-dilutive funding and validate platform capabilities [news · 2026-09-10][news · 2025-12-09]
- Strategic partnerships in AI drug discovery (Inductive Bio) and in vivo CAR therapies (STRM.BIO, UBC) expand revenue potential [news · 2025-08-20][news · 2025-10-23]
- Shareholders' equity of $420.3M as of 2026-06-30 provides a substantial capital base [sec]
What to weigh
- Net loss of $46.7M for the six months ended June 30, 2026, indicating ongoing cash burn [sec]
- Company anticipates expenditures will exceed revenue through at least the next 12 months [sec_mda · as of 2026-08-06]
- Restructuring charges from a reduction in force commenced in June 2024 continue to impact financials [sec_mda · as of 2026-08-06]
From the filings
Quoted directly from source documents.
ARPA-H GIVE subcontract award
“awarded a subcontract for up to $17.5M under the Advanced Research Projects Agency for Health’s (ARPA-H) Genetic Medicines and Individualized Manufacturing for Everyone (GIVE) program”
News · September 10, 2026
Expenditures expected to exceed revenue for at least 12 months
“We anticipate that our expenditures will exceed our revenue through at least the next 12 months”
SEC MD&A · August 6, 2026
Catalyst timeline
- 2026-08-05 · Earnings Report - SEC 8-K filing — Upcoming earnings report for Q2 2026; will provide updated financials and business update.
Risks & what to watch (3)›
Key risks
- Cash burn rate — Net loss of $46.7M in six months to 2026-06-30; cash of $84.5M may be consumed within ~1 year if losses continue [sec]
- Revenue insufficient to cover costs — Company states expenditures will exceed revenue through at least next 12 months [sec_mda · as of 2026-08-06]
- Restructuring costs — Restructuring charges from June 2024 workforce reduction continue to affect financial results [sec_mda · as of 2026-08-06]
What to watch
- Q2 2026 business performance presentation on August 5, 2026 [news · 2026-07-30]
- Progress and follow-on funding from ARPA-H GIVE program for RNA medicine manufacturing [news · 2026-09-10]
- Revenue growth from AI drug discovery partnership with Inductive Bio [news · 2025-08-20]
- Cash runway and any additional ATM offerings under the $100M Sales Agreement [sec_mda · as of 2026-08-06]
Sources: Catalysts · Competitor trials · News · SEC MD&A · Generated October 8, 2026 · How we verify sources →
Run Ginkgo Bioworks Holdings Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Ginkgo Bioworks Holdings Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 1.36
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
0 buys · 3 sells (180d)
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
173
Total value held
$195.4M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 3,642,347 | $22.3M |
| viking global investors lp | 3,577,128 | $21.9M |
| baillie gifford & co | 2,391,649 | $14.7M |
| vanguard capital management llc | 1,914,428 | $11.7M |
| anchorage capital group, l.l.c. | 1,746,363 | $10.7M |
| erste asset management gmbh | 1,947,728 | $10.7M |
| legal & general group plc | 1,661,587 | $10.2M |
| state street corp | 1,346,659 | $8.3M |
| forbes j m & co llp | 1,028,391 | $6.3M |
| geode capital management, llc | 1,009,362 | $6.2M |
Showing top 10 of 173 institutional holders of Ginkgo Bioworks Holdings Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 10.1%
- Days to cover
- 4.7
- Shares short
- 5,233,195
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
DNA short interestGovernance
Frequently asked questions
What is the AI investment thesis for Ginkgo Bioworks Holdings Inc.?
Ginkgo Bioworks Holdings Inc. (DNA) is a synthetic biology company focused on cell programming and biosecurity, with a current cash position of $84.5M as of 2026-06-30 and ongoing partnerships in RNA medicine and AI drug discovery.
Who is the CEO of Ginkgo Bioworks Holdings Inc.?
Dr. Jason Kelly Ph.D. is the chief executive officer of Ginkgo Bioworks Holdings Inc. (DNA).
Where is Ginkgo Bioworks Holdings Inc. headquartered?
Ginkgo Bioworks Holdings Inc. (DNA) is headquartered in Boston, MA, United States.
What therapeutic areas does Ginkgo Bioworks Holdings Inc. focus on?
Ginkgo Bioworks Holdings Inc. develops therapies across Pain.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.